Proxima Clinical Research, a contract research organization (CRO), is expanding its early phase oncology clinical trials offering with its Early Phase Oncology Network, a group of oncology-specific scientific experts and early phase clinical trials clinics that allows for quick and easy site enrollment and expert insight, feedback, and guidance in first-in-human Phase I and Phase II clinical oncology trials.

“The CRO’s job is to move innovative therapies through the FDA journey to market as quickly, efficiently, and cost-effectively as possible,” said Robbin Frnka, executive director CRO. “Finding the right clinical sites and investigators with the right patients is one of the biggest struggles of early phase clinical trials. Our early phase oncology network, which we’re calling EPON, includes some of the most prominent of clinical development and strategy at Proxima investigators in early phase trials.”

Mary Crowley Cancer Research is a specialized clinical research center in Dallas, Texas that offers access to new investigational therapies through the administration of Phase I and II clinical trials. An early adopter within the Proxima CRO EPON network, the research sites work collaboratively to advance groundbreaking cancer research.

“Proxima CRO’s EPON is a valuable asset for Mary Crowley Cancer Research, expanding our access to more innovative clinical trials which helps us save more lives,” said Jennifer Fox, interim CEO of Mary Crowley Cancer Research. “Our comprehensive team provides investigational therapies through the administration of clinical trials to patients in need. Our work with Proxima empowers our vital mission with its in-depth and efficient network.”